Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R et al (2020a) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21:671–684

Article  PubMed  PubMed Central  CAS  Google Scholar 

Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J et al (2020b) Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21:796–807. https://doi.org/10.1016/S1470-2045(20)30157-1

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ahn KS, O’Brien D, Kang YN, Mounajjed T, Kim YH, Kim T-S et al (2019) Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular–clinical analysis and potential targeted approach. Hepatol Int 13:490–500

Article  PubMed  Google Scholar 

Akita M, Sofue K, Fujikura K, Otani K, Itoh T, Ajiki T et al (2019) Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma. HPB 21:226–234. https://doi.org/10.1016/j.hpb.2018.07.021

Article  PubMed  Google Scholar 

Akita M, Fujikura K, Ajiki T, Fukumoto T, Otani K, Azuma T et al (2017) Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. Mod Pathol. 30:986–997

Article  PubMed  CAS  Google Scholar 

Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS (2015) Treatment of unresectable intrahe-patic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 41(1):120–127

Article  PubMed  PubMed Central  CAS  Google Scholar 

Banales JM, Cardinale V, Marzioni M, Andersen JB, Inverzinni P, Lind GE et al (2016) Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Rev Gastroenterol Hepatol 13:261–280

Article  Google Scholar 

Banales JM, Marin JJG, Lamarca A et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17(9):557–588

Article  PubMed  PubMed Central  Google Scholar 

Ben-Josef E, Guthrie KA, El-Khoueiry AB et al (2015) SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol 33(24):2617–2622

Article  PubMed  CAS  Google Scholar 

Benson AB, D’Angelica MI, Abbott DE, Anaya DA, Anders R, Are C et al (2021) Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19:541–565

Article  PubMed  Google Scholar 

Bertuccio P, Malvezzi M, Carioli G et al (2019) Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol 71(1):104–114

Article  PubMed  Google Scholar 

Bridgewater J, Galle PR, Khan SA, Llovet JM, Park J-W, Patel T et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268–1289

Article  PubMed  Google Scholar 

Bridgewater J, Fletcher P, Palmer DH et al. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.

Chung T, Rhee H, Nahm JH, Jeon Y, Yoo JE, Kim Y-J et al (2020) Clinicopathological characteristics of intrahepatic cholangiocarcinoma according to gross morphologic type: cholangiolocellular differentiation traits and inflammation- and proliferation-phenotypes. HPB 22:864–873. https://doi.org/10.1016/j.hpb.2019.10.009

Article  PubMed  Google Scholar 

Chung T, Rhee H, Shim HS, Yoo JE, Choi GH, Kim H et al (2021) Genetic, clinicopathological, and radiological features of intrahepatic cholangiocarcinoma with ductal plate malformation pattern. Gut Liver. https://doi.org/10.5009/gnl210174

Article  PubMed  PubMed Central  Google Scholar 

Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA (2020) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol 72:95–103

Article  PubMed  Google Scholar 

EASL Clinical Practice Guidelines on genetic cholestatic liver diseases. https://doi.org/10.1016/jhep.2024.04.006.

EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. Journal of Hepatology, July 2023. Vol. 79, 181–208.

Deutsche S-3 Leitlinie: Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome. Version 4.0 – August 2024. AWMF-Registernummer: 032–053OL.

Ebata T, Hirano S, Konishi M et al (2018) Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 105(3):192–202

Article  PubMed  CAS  Google Scholar 

Edeline J, Benabdelghani M, Bertaut A et al (2019) Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 37(8):658–667

Article  PubMed  CAS  Google Scholar 

Edeline J, Lamarca A, McNamara MG et al (2021) Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. Cancer Treat Rev 99:102258

Article  PubMed  Google Scholar 

Edeline J, Bridgewater J, Campillo-Gimenez B et al (2024) Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: data from clinical trials. Hepatology 79:96–106

Article  PubMed  Google Scholar 

Glantzounis GK, Tokidis E, Basourakos S-P, Ntzani EE, Lianos GD, Pentheroudakis G (2017) The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. European J Surgical Oncol (EJSO) 43:32–41

Article  CAS  Google Scholar 

Goetze TO et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the phase III AIO/CALGP/ACO-GAIN-Trial. Journal of Clinical Oncology, Volume 43, Nzmber 16 suppl. Meeting abstract: 2025 ASCO Annual meeting.

Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB et al (2023) Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med. 388(3):228–239

Article  PubMed  CAS  Google Scholar 

Gudbjartsson DF et al (2015) Large-scale whole-genome sequencing of the Icelandic population. Nat Genet 47:435–444

Article  PubMed  CAS  Google Scholar 

Hayashi A, Misumi K, Shibahara J, Arita J, Sakamoto Y, Hasegawa K et al (2016) Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma. Am J Surg Pathol 40:1021–1030. https://doi.org/10.1097/PAS.0000000000000670

Article  PubMed  Google Scholar 

Hirohashi K, Uenishi T, Kubo S, Yamamoto T, Tanaka H, Shuto T et al (2002) Histologic bile duct invasion by a mass-forming intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 9:233–236. https://doi.org/10.1007/s005340200024

Article  PubMed  Google Scholar 

Ikeda M, Nakachi K, Konishi M et al (2022) Adjuvant S-1 versus observation in curatively resected biliary tract cancer: a phase III trial (JCOG1202: ascot). J Clin Oncol 40(suppl_4):382

Article  Google Scholar 

Isaji S, Kawarada Y, Taoka H, Tabata M, Suzuki H, Yokoi H (1999) Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg 6:108–116

Article  PubMed  CAS  Google Scholar 

Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH et al (2021a) Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 6:803–815

Article  PubMed  Google Scholar 

Javle M, Borad MJ, Azad NS et al (2021b) Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 22(9):1290–1300

Article  PubMed  CAS  Google Scholar 

Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1853–1865

Article  PubMed  Google Scholar 

Kendre G et al (2023) Charting co-mutation patterns assocciated with actionable drivers in intrahepatic cholangiocarcinoma. J Hepatol 78(3):614–626

Article  PubMed  CAS  Google Scholar 

Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP et al (2012) Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 61:1657–1669